Addario Lung Cancer Medical Institute
Addario Lung Cancer Medical Institute
Want to make a donation using Daffy?
Lower your income taxes with a charitable deduction this year when you donate to this non-profit via Daffy.
Do you work for Addario Lung Cancer Medical Institute? Learn more here.
About this organization
Mission
THE ADDARIO LUNG CANCER MEDICAL INSTITUTE (ALCMI) CONDUCTS COLLABORATIVE RESEARCH INITIATIVES IN GENETIC (MOLECULAR) TESTING, THERAPEUTIC DISCOVERIES, TARGETED TREATMENTS AND EARLY DETECTION. ALCMI OVERCOMES BARRIERS TO COLLABORATION VIA A WORLD-CLASS TEAM OF INVESTIGATORS FROM 25 MEMBER INSTITUTIONS, SUPPORTED BY DEDICATED, CENTRALIZED RESEARCH INFRASTRUCTURES SUCH AS STANDARDIZED BIOREPOSITORIES AND DATA SYSTEMS. ALCMI DIRECTLY FACILITATES RESEARCH BY COMBINING SCIENTIFIC EXPERTISE FOUND AT LEADING ACADEMIC INSTITUTIONS WITH PATIENT ACCESS THROUGH ITS NETWORK OF COMMUNITY CANCER CENTERS ACCELERATING NOVEL RESEARCH ADVANCEMENTS TO LUNG CANCER PATIENTS. BY PROVIDING ACCESS TO CRITICAL MASSES OF PATIENT STAKEHOLDERS, ACADEMIC, COMMUNITY AND INDUSTRY RESEARCHERS, ALCMI IS MAKING PROGRESS TOWARDS ITS GOAL OF TRANSFORMING LUNG CANCER INTO A CHRONICALLY MANAGED DISEASE BY 2023.
About
RESEARCH - THE ADDARIO LUNG CANCER MEDICAL INSTITUTE (ALCMI) IS DEDICATED TO CATALYZING AND ACCELERATING THE DISCOVERY, DEVELOPMENT AND DELIVERY OF NEW AND MORE EFFECTIVE TREATMENT OPTIONS FOR LUNG CANCER PATIENTS. ALCMI IS A PATIENT-FOUNDED, PATIENT-FOCUSED RESEARCH CONSORTIUM. ITS GOAL IS TO MAKE LUNG CANCER A CHRONICALLY MANAGED DISEASE. ALCMI WAS CREATED IN 2008, AS A PARTNER ORGANIZATION WITH THE BONNIE J ADDARIO LUNG CANCER FOUNDATION (ALCF), TO ENABLE THE COLLECTION AND ANALYSIS OF TISSUE AND BLOOD SAMPLES WHICH ARE ESSENTIAL TO RESEARCH AND TO THE DEVELOPMENT OF INDIVIDUALLY TAILORED (AND MORE EFFECTIVE) THERAPIES. ALCMI IS UNIQUE. IT IS A COMPREHENSIVELY CONTRACTED CONSORTIUM WITH SHARED INFRASTRUCTURES (STANDARDIZED CONTRACTS, DATA SYSTEMS AND BIOREPOSITORIES) AND CENTRALLY COORDINATED SCIENTIFIC PLANNING. ALCMI'S RESEARCHERS ARE POOLING THEIR KNOWLEDGE, SPECIMENS AND DATA IN ORDER TO IMPROVE THE UNDERSTANDING OF THE MOLECULAR BASES OF LUNG CANCER AND TO ACCELERATE THE DEVELOPMENT AND DELIVERY OF MUCH MORE EFFECTIVE, TARGETED DRUGS AND TREATMENTS TAILORED TO INDIVIDUAL PATIENTS. ALCMI HAS DEVELOPED AND LAUNCHED THREE INNOVATIVE RESEARCH STUDIES THAT WOULD OTHERWISE NOT HAVE EXISITED: 1) CASTLE PROSPECTIVE, LONGITUDINAL, MULTI-CENTER STUDY WITH BIOBANK, ANNOTATED WITH CLINICAL/MOLECULAR DATA AND MATCHED, SERIAL BIOSPECIMENS FROM ADVANCED STAGE LUNG CANCER; 2) INHERIT EGFR T790M: PROSPECTIVE STUDY ON GERMLINE BIOLOGY IN HIGH-RISK FAMILIES, TO IDENTIFY SPECIFIC INHERITED GENETIC MARKERS INDICATING RIKS OF DEVELOPING LUNG CANCER; AND 3) GENOMICS OF YOUNG LUNG CANCER: PROSPECTIVELY PERFORM COMPREHENSIVE GENOMIC PROFILING TO DETERMINE WHETHER YOUNG LUNG CANCERS HARBOR A DISTINCTIVE SPECTRUM OF GENETIC MUTATIONS, AND THEREFORE UNIQUE TREATMENT STRATEGIES.
Interesting data from their 2020 990 filing
The non-profit's mission, as documented in the filing, is “The addario lung cancer medical institute (alcmi) is dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients.”.
When explaining its purpose, the activities were described as: “The addario lung cancer medical institute (alcmi) conducts collaborative research initiatives in genetic (molecular) testing, therapeutic discoveries, targeted treatments and early detection. alcmi overcomes barriers to collaboration via a world-class team of investigators from 25 member institutions, supported by dedicated, centralized research infrastructures such as standardized biorepositories and data systems. alcmi directly facilitates research by combining scientific expertise found at leading academic institutions with patient access through its network of community cancer centers accelerating novel research advancements to lung cancer patients. by providing access to critical masses of patient stakeholders, academic, community and industry researchers, alcmi is making progress towards its goal of transforming lung cancer into a chronically managed disease by 2023.”.
- The non-profit is legally allowed to operate in the state of CA, as reported.
- The filing provides the non-profit's address in 2020 as 1100 INDUSTRIAL ROAD NO 1, SAN CARLOS, CA, 94070.
- The non-profit has a total of 2 employees, as reported on their form for 2020.
- Is not a private foundation.
- Expenses are between $500,000 and $1,000,000+.
- Revenue is greater than $1,000,000.
- Revenue less expenses is $323,112.
- The organization has 5 independent voting members.
- The organization was formed in 2008.
- The organization pays $549,322 in salary, compensation, and benefits to its employees.
- The organization pays $54,687 in fundraising expenses.
Additional Non-Profits in the area
By donating on this page you are making an irrevocable contribution to Daffy Charitable Fund, a 501(c)(3) public charity, and a subsequent donation recommendation to the charity listed above, subject to our Member Agreement. Contributions are generally eligible for a charitable tax-deduction and a yearly consolidated receipt will be provided by Daffy. Processing fees may be applied and will reduce the value available to send to the end charity. The recipient organizations have not provided permission for this listing and have not reviewed the content.
Donations to organizations are distributed as soon as the donation is approved and the funds are available. In the rare event that Daffy is unable to fulfill the donation request to this charity, you will be notified and given the opportunity to choose another charity. This may occur if the charity is unresponsive or if the charity is no longer in good standing with regulatory authorities.